Schizophrenia
Schizophrenia is a complex psychiatric disorder characterised by disruptions in thought processes and perception. Recent research into psychedelics has opened new avenues for understanding its neurobiology and exploring potential therapeutic mechanisms, particularly in addressing treatment-resistant symptoms.
Key Insights
- 1
Early psychedelic studies highlighted the potential for classic hallucinogens to model psychosis, benefitting the understanding of schizophrenia’s neurobiology. Though modern research calls into question if psychedelics can mimic psychosis.
- 2
Modern research is investigating the utility of psychedelics as tools to inform the development of novel antipsychotic agents, rather than as direct treatments.
- 3
Psychological therapies combined with innovative compounds targeting different neurotransmitter systems are being explored to address treatment-resistant symptoms effectively.
What is Schizophrenia?
Schizophrenia is a chronic mental health disorder defined by episodes of psychosis, during which individuals experience hallucinations, delusions, and disorganised speech. It arises from a combination of genetic, neurobiological, and environmental factors, with structural abnormalities often observed in the prefrontal cortex and dopamine pathways.
The symptoms of schizophrenia are grouped into positive symptoms (hallucinations, delusions), negative symptoms (emotional blunting, lack of motivation), and cognitive symptoms (memory and concentration deficits). Diagnosis is based on the presence of these symptoms over a significant duration.
Neurobiological research implicates the serotonin system, particularly the 5-HT2A receptor, in the pathophysiology of schizophrenia, alongside disruptions in neurotransmitter systems like dopamine and glutamate.
Current Treatments
Standard treatment for schizophrenia involves antipsychotic medications, which primarily target dopamine pathways, often complemented by psychotherapy and social rehabilitation. However, these treatments frequently fail to adequately address negative and cognitive symptoms.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Schizophrenia.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Modern research supports psilocybin's role in enhancing neuroplasticity and connectivity which may potentially alleviate cognitive symptoms. | Medium | Moderate | Consistent |
| LSD Current studies explore LSD's neurobiological insights rather than therapeutic application due to the risk of exacerbating symptoms. | Medium | Moderate | Consistent |
| Ketamine Ketamine shows promise in quick relief of depressive symptoms and cognitive deficits in schizophrenia, supported by substantial clinical evidence. | Large | High | Consistent |
| MDMA MDMA's potential to enhance social engagement has been observed, but its therapeutic efficacy in schizophrenia is still under investigation. | Medium | Moderate | Inconsistent |
Ketamine and Schizophrenia
Ketamine, primarily an NMDA receptor antagonist, offers rapid relief from depressive symptoms and is being evaluated for its potential to address cognitive deficits in schizophrenia. Its unique mechanism differentiates it from classical psychedelics, thereby presenting both benefits and risks, including the possibility of exacerbating psychotic symptoms.
MDMA and Schizophrenia
MDMA has been investigated for its ability to improve emotional and social functioning, specifically targeting the negative symptoms of schizophrenia. Research indicates that, if administered in conjunction with therapy, MDMA may enhance emotional processing and reduce social withdrawal, yet its long-term safety and efficacy necessitate further study.
Clinical Outlook
As research progresses, the potential for psychedelics and their analogues to provide insights into the neurobiology of schizophrenia is promising. Future developments in drug formulation may lead to safer, non-hallucinogenic options that effectively target both cognitive and negative symptoms inherent in schizophrenia.
Industrial Landscape
Key players in this field include Delix Therapeutics, MindMed, and Compass Pathways, which are exploring psychedelic-inspired compounds and non-hallucinogenic options aimed at improving cognitive and negative symptoms associated with schizophrenia.
Quick Indicators
Organisations
Search →University of Arizona
Although the University of Arizona may not have a dedicated psychedelic research group, one of the first modern clinical trials investigating the use of psychedelics to treat a mental disorder was conducted at the University. In 2006, Dr Francisco Moreno led the first FDA-approved study in 25 years using psychedelics at UA. The study examined the use of psilocybin to treat symptoms of obsessive-compulsive disorder (OCD). Since then, researchers within the Department of Psychiatry at UA have maintained their interest in the field. Dr Moreno, along with Dr Brian Bayze and their research group, is continuing to conduct research into this particular area of psychedelic science at UA ever since the 2006 trial. There is a trial underway at UA exploring the effects of psilocybin on OCD.
National Institutes of Health (NIH)
U.S. federal biomedical research agency shaping institute-level priority and research funding architecture.
People
Search →Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Erich Studerus
Psychologist and Scientific Director at fepsy Basel; Lecturer at FHNW
He is a recurring author on influential human psychedelic studies, especially on psilocybin, LSD, MDMA, and ayahuasca effects and predictors of response.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Kruti Joshi
Employee at Janssen Scientific Affairs, LLC
Joshi appears to be a Janssen-affiliated researcher coauthoring multiple real-world evidence studies on esketamine access, barriers, utilization, and economic outcomes in treatment-resistant depression.
Devon Stoliker
Research Fellow / PhD Student at Monash University’s Turner Institute for Brain and Mental Health
Devon Stoliker is notable for mechanistic psychedelic neuroscience research using dynamic causal modeling and fMRI to study ego dissolution, connectivity, and context-dependent effects of psilocybin and LSD.
Gary Egan
Distinguished Professor and Foundation Director of Monash Biomedical Imaging
He is a leading neuroimaging researcher whose work has helped elucidate the brain mechanisms of psychedelics, including psilocybin- and LSD-related changes in connectivity, ego dissolution, and visual imagery.
Connected Evidence
The latest clinical data and verified academic findings associated with Schizophrenia.